GlaxoSmithKline releases positive data on Shingrix efficacy
GSK
1,299.00p
15:45 15/11/24
-4.03%
-54.50p
GlaxoSmithKline released new data from a Phase III clinical study on Wednesday, which it said supports the safety and efficacy of Shingrix in preventing shingles when given to adults 18 years and above shortly after undergoing autologous haematopoietic stem cell transplant.
FTSE 100
8,060.61
15:45 15/11/24
n/a
n/a
FTSE 350
4,453.56
15:45 15/11/24
n/a
n/a
FTSE All-Share
4,411.85
15:45 15/11/24
n/a
n/a
Pharmaceuticals & Biotechnology
19,259.77
15:45 15/11/24
-2.70%
-535.19